Drugs / IGN523
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02040506 | Feb 2014 → Mar 2015 | acute myeloid leukemia | Igenica Biotherapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGN523 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02040506 ↗ |
| Known as | AML-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594556 ↗ |
| Route | Intravenous | “IGN523 administered as an IV infusion” NCT02040506 ↗ |